GLP-1 and Male Fertility: Sperm Quality and Weight
Understand the relationship between GLP-1 medications, weight loss, and male fertility. Learn how obesity affects sperm quality and what research shows about semaglutide, tirzepatide, and reproductive health.
More on Men's Health
Important for Men Planning Families
If you are actively trying to conceive or planning to start a family within the next year, discuss your GLP-1 therapy with both your prescribing provider and a reproductive specialist. While evidence suggests GLP-1 medications are not harmful to male fertility, individualized guidance is important during this critical life stage.
How Obesity Damages Male Fertility
Male obesity is an increasingly recognized cause of infertility and subfertility. As obesity rates have risen over the past several decades, sperm counts in Western countries have declined by approximately 50% — a trend that many researchers believe is partially driven by the obesity epidemic.
Hormonal disruption is the primary mechanism. As discussed in our GLP-1 and testosterone guide, excess fat tissue converts testosterone to estrogen through aromatase. This hormonal imbalance directly impairs spermatogenesis (sperm production) in the testes. Low testosterone reduces the signals that drive sperm cell development, while elevated estrogen suppresses the hypothalamic-pituitary-gonadal axis that controls the entire reproductive system.
Scrotal temperature increases with obesity. Excess fat around the thighs and lower abdomen insulates the testicles, raising scrotal temperature above the optimal range for sperm production. Even a 1-2 degree Celsius increase can significantly impair spermatogenesis. Sedentary behavior, common in obese men, further contributes to scrotal heating.
Oxidative stress and inflammation from obesity damage sperm DNA. Obese men have significantly higher levels of reactive oxygen species in seminal fluid, leading to increased sperm DNA fragmentation. High DNA fragmentation is associated with lower fertilization rates, poorer embryo development, and higher miscarriage risk even when sperm counts and motility appear adequate.
Epigenetic changes represent a newer area of concern. Obesity alters the epigenetic marks (DNA methylation patterns) on sperm, which can be passed to offspring. Studies suggest that paternal obesity at the time of conception may increase the child's risk of metabolic disease, though this research is still evolving.
Weight Loss and Sperm Quality Improvement
The good news is that obesity-related fertility impairment is largely reversible with weight loss. Multiple studies demonstrate that losing 10-15% of body weight — the typical result with GLP-1 medications — significantly improves sperm parameters.
A systematic review of weight loss and male fertility found that men who lost an average of 15% body weight saw sperm concentration increase by 35-40%, total motile sperm count improve by 45-50%, and sperm DNA fragmentation decrease by 25-35%. These improvements correlated with rising testosterone levels and declining estradiol levels — exactly the hormonal changes produced by GLP-1 therapy.
The timeline for improvement follows the biology of sperm production. Spermatogenesis takes approximately 74 days, so any changes in the hormonal environment or testicular function take about 2.5-3 months to manifest in ejaculated sperm. Men who begin GLP-1 therapy and experience significant weight loss in the first 3-4 months can expect to see measurable sperm quality improvements around months 5-8 of treatment.
GLP-1 Medications and Direct Reproductive Effects
Beyond the indirect benefits of weight loss, researchers are investigating whether GLP-1 receptor agonists have direct effects on male reproductive organs. GLP-1 receptors have been identified in the testes, though their exact function is not yet fully understood.
Animal studies have produced mixed results. Some rodent studies at very high doses showed reduced testicular weight and sperm counts, but these doses were far higher (relative to body weight) than therapeutic doses used in humans. Studies at human-equivalent doses have generally shown no adverse effects on testicular function or sperm parameters.
Human data, while limited, is reassuring. Post-hoc analyses of male participants in the STEP and SURMOUNT trials have not identified reproductive safety signals. A 2025 retrospective study of over 5,000 men prescribed semaglutide found no increase in male infertility diagnoses compared to matched controls, and men who had semen analyses before and during treatment showed improvements consistent with their degree of weight loss.
It is important to note that for women, the recommendation is to stop GLP-1 medications at least 2 months before conception due to unknown effects on fetal development. For men, the concern is different — sperm are produced continuously, and the medication does not remain in the body at the time of conception in any meaningful way. Current evidence does not support stopping GLP-1 medications in the male partner when trying to conceive.
Practical Recommendations for Men
If planning a family in 6-12 months: GLP-1-assisted weight loss can be an excellent strategy to improve fertility before conception. Starting treatment 6-12 months before planned conception gives time for weight loss and hormonal normalization to translate into improved sperm quality.
If actively trying to conceive: Consider a semen analysis to establish your baseline. Continue GLP-1 therapy unless your reproductive endocrinologist advises otherwise. Focus on adequate nutrition, especially zinc, folate, and antioxidants.
Supplement wisely: CoQ10 (200-400mg daily), zinc (30mg daily), folate, vitamin C, and vitamin E have evidence supporting sperm quality improvement and pair well with GLP-1 therapy.
Avoid excessive heat: Hot tubs, saunas, and prolonged sitting can further impair sperm production. During GLP-1 therapy, avoid additional testicular heat stress.
Get follow-up testing: If baseline semen analysis was abnormal, repeat testing 3-6 months after starting GLP-1 therapy to track improvements alongside your weight loss progress.
Medical Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice. Male fertility is complex and affected by many factors beyond weight. If you are experiencing difficulty conceiving, consult a reproductive endocrinologist or urologist specializing in male infertility for comprehensive evaluation.
Frequently Asked Questions
Can GLP-1 medications harm sperm quality?
Current evidence does not show that GLP-1 medications directly harm sperm quality. In fact, by reducing obesity and improving hormonal balance, GLP-1 therapy may improve sperm parameters in overweight men. However, the rapid hormonal changes during weight loss can temporarily affect fertility, so men actively trying to conceive should discuss timing with their provider.
Should I stop GLP-1 medication if trying to conceive?
There is no current recommendation to stop GLP-1 medications when trying to conceive as a male partner. Unlike the female recommendation to stop 2 months before conception, male reproductive effects are primarily positive through weight loss. However, discuss your specific situation with both your prescribing provider and a fertility specialist.
Does obesity really affect sperm?
Yes, extensively. Obese men have lower sperm counts, reduced sperm motility, more DNA fragmentation in sperm, and higher rates of abnormal sperm morphology. Obesity also causes hormonal disruption (low testosterone, high estrogen) that impairs sperm production. Studies show that losing 10-15% of body weight can significantly improve all these parameters.
How long after weight loss does sperm quality improve?
Sperm production takes approximately 74 days (about 2.5 months) from start to finish. After significant weight loss and hormonal improvement, you can expect to see measurable improvements in sperm parameters within 3-6 months. Maximum improvement may take 6-12 months as the full hormonal and metabolic benefits of weight loss take effect.
Optimize Your Health for the Future
Improving your metabolic health through GLP-1 therapy may benefit your fertility and your future family's health.
Consult with a ProviderSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).